Micafungin (MCFG) is an echinocandin antifungal drug used for prophylaxis and treatment of fungal infections after allogeneic hematopoietic cell transplantation (HCT). However, its efficacy and safety in patients undergoing cord blood transplantation (CBT) has not been clarified. We retrospectively analyzed the efficacy and safety of MCFG in 92 adult patients undergoing CBT in our institute. Of the entire cohort, 83 patients (90%) received MCFG for empirical or preemptive therapy. Documented breakthrough fungal infection occurred in 2 patients during MCFG treatment. Among the 49 patients who received MCFG as empirical therapy for febrile neutropenia, 41 (84%) patients had resolution of fever during neutropenia. Elevation of serum levels of hepatobiliary parameters during MCFG treatment was commonly observed, but grade 3 or higher elevation was rare. We also compared the efficacy and safety of 2 different initial daily doses of MCFG (150 mg vs. 300 mg). There were no significant differences of efficacy and safety between the two groups. These data suggest that MCFG was effective and safe for adult patients undergoing CBT. The optimal daily dose of MCFG treatment is a matter of future investigation for adult patients undergoing CBT.

中文翻译：

---

米卡芬净在无关的脐血移植受者中的疗效和安全性。

米卡芬净（MCFG）是一种棘皮菌素抗真菌药，用于预防和治疗同种异体造血细胞移植（HCT）后的真菌感染。但是，其在接受脐血移植（CBT）的患者中的疗效和安全性尚未阐明。我们回顾性分析了我院92例接受CBT的成年患者MCFG的疗效和安全性。在整个队列中，有83例（90％）患者接受了MCFG的经验性或先发性治疗。有记录的MCFG治疗期间有2例患者发生了突破性真菌感染。在接受MCFG作为高热性中性粒细胞减少症的经验疗法的49名患者中，有41名（84％）患者在中性白细胞减少症期间发烧了。通常观察到MCFG治疗期间血清肝胆参数水平升高，但是3级以上的海拔很少见。我们还比较了2种不同的每日初始MCFG剂量（150 mg与300 mg）的疗效和安全性。两组之间的疗效和安全性无显着差异。这些数据表明，MCFG对于接受CBT的成年患者是安全有效的。对于接受CBT的成年患者，MCFG治疗的最佳每日剂量是未来研究的问题。